Glioblastoma is the most common and malignant form of brain cancer. Its invasive nature limits 23 treatment efficacy and promotes inevitable recurrence. Previous in vitro studies have shown that 24 interstitial fluid flow, a factor characteristically increased in cancer, increases glioma cell invasion via 25 CXCR4-CXCL12. It is currently unknown if these effects translate in vivo. Using the therapeutic 26 technique of convection enhanced delivery (CED), we tested if convective flow alters glioma invasion in 27 vivo using the syngeneic GL261 mouse model of glioblastoma. We first confirmed that GL261 invasion 28 in vitro increased under flow in a CXCR4-CXCL12 dependent manner. Additionally, approximately 29 65.4% and 6.59% of GL261 express CXCR4 and CXCL12 in vivo, respectively, with 3.38% expressing 30 both. Inducing convective flow within implanted tumors indeed increased glioma cell invasion over 31 untreated controls, and administering CXCR4 antagonist AMD3100 (5 mg/kg) effectively eliminated this 32 response. Therefore, glioma invasion is in fact stimulated by convective flow in vivo through CXCR4. We 33 also analyzed patient samples to show that expression of CXCR4 and CXCL12 increase in patients 34 following therapy. These results suggesting that targeting flow-stimulated invasion may prove beneficial 35 as a second line of therapy, particularly in patients chosen to receive convection enhanced drug delivery. 36 from the vasculature throughout the interstitial tissue space toward draining lymphatics or clearance
Introduction 37
Glioblastoma (GBM) is the most aggressive form of brain cancer and is characterized by invasion 38 into the surrounding brain or parenchyma 1, 2 . This invasiveness causes diffuse borders between the tumor 39 and parenchyma, preventing effective resection of all malignant cells. Additionally, because tumor cells 40 that have invaded into the surrounding healthy tissue are increasingly resistant to radiation and 41 chemotherapy, GBM always recurs 3,4 . Therefore, understanding and targeting molecules that regulate 42 glioma cell invasion has therapeutic implications in the treatment of GBM. One signaling axis known to 43 regulate GBM invasion is the CXCR4-CXCL12 pathway. While a potent driver of GBM invasion in 44 static conditions, CXCR4-and CXCL12-mediated invasion in GBM can be enhanced by interstitial fluid 45 flow through a mechanism known as autologous chemotaxis [5] [6] [7] . Interstitial flow is the movement of fluid 46 47 pathways. This process normally acts to maintain tissue homeostasis, but the leaky nascent vasculature 48 and increased waste production in solid cancers can dramatically increase interstitial pressure and, in turn, 49 interstitial flow 1, 8 . 50
We previously showed that rat and human GBM cell lines respond to flow in vitro by increasing 51 invasion 6,7 . Furthermore, regions of high flow (identified by arterial extravasation of Evans blue) 52 correlated with regions of invasion for cell lines as well as patient-derived glioma stem cells 6,7 . Flow-53 stimulated invasion was mitigated by both blocking the receptor CXCR4 as well as saturating the ligand 54 CXCL12, suggesting this chemokine-receptor pathway plays a key role in glioma cell flow response. It 55 remains unknown, however, if interstitial flow directly stimulated cancer cell invasion in vivo and if 56 CXCR4 signaling was similarly implicated. Answering these questions requires a technique to induced 57 convective forces within the tumor in situ at a time when heightened interstitial flow may not be fully 58 established on its own. 59
Convection enhanced delivery (CED) is an experimental technique used in the clinic to overcome 60 high intra-tumoral pressure and increase drug distribution via local infusion 9,10 . A blunt needle is placed 61 into the center of the tumor, and a drug-laden solution is infused to drive drug transport. In essence, CED 62 drives convective flow through the interstitial spaces in the tumor, mimicking interstitial fluid flow. We 63 used CED in a murine model of GBM to test the hypothesis that convective flow directly stimulates 64 cancer cell invasion in vivo and examine the dependence of this response on CXCR4 signaling. 65
Results

66
GL261 exhibit flow-stimulated invasion in vitro in a CXCR4-dependent manner 67
Prior to in vivo assessment, the flow response of GL261 cells was examined in vitro using a 3D tissue 68 culture insert model ( Fig. 1A ) 6 . Under static conditions, 0.1-0.2% of GL261 invaded beyond the semi-69 permeable membrane (Fig. 1B) . The addition of gravity-driven flow significantly increased the percent of 70 p<0.01). This flow-stimulated increase in invasion could be 72 mitigated by blocking CXCR4 using 10 µM AMD3100, a 73 small molecule inhibitor of CXCR4 (t(4)=2.722, n=5, p>0.1). 74
Similar results were observed for saturating the cultures (in 75 the gel and both sides of the transwell) with 100 nM 76 CXCL12. Ligand saturation significantly decreased the 77 effects of flow (t(4)=3.545, n=5, p<0.05) (Fig. 1C) , returning 78 invasion to untreated levels (t(3)=2.293, n=4, p>0.1). Hence, 79 the flow response of GL261 aligns with the previously 80 proposed mechanism of CXCR4-CXCL12 autologous 81 chemotaxis 1 . 82 CXCR4 + and CXCR4 + CXCL12 + populations are enriched 83 within in vivo tumor samples 84
Because the significance of targeting autologous 85 chemotaxis and flow-stimulated invasion may be influenced 86 by expression levels, we used flow cytometry to characterize 87 GL261 expression of CXCR4 and CXCL12 in different 88 environments. The dimensionality of culture significantly 89 impacted receptor and ligand expression. In 2D, few cells 90 expressed the receptor, ligand, or both ( Fig. 2) . Embedding the cells in 3D hydrogels significantly 91 increased the number of CXCR4 + cells to 8.13 ± 1.71% compared to 1.83 ± 0.25% in 2D culture 92 (t(3)=3.389, n=4, p<0.05) ( Fig. 2A) . Similar effects were observed on the CXCL12 population (t(3)=4.14, 93 n=4, p<0.05) ( Fig. 2B) . While there was no difference in the percentage of CXCR4 + CXCL12 + cells 94 between 2D and 3D in vitro culture ( Fig. 2C) , this double positive population increased from 1.66 ± 95 3B. First, magnetic resonance imaging was used to verify the ability to induce fluid convection using 120 CED. A gadolinium contrast agent conjugated to albumin (Galbumin, 25 mg/mL) was infused into the 121 tumors at day 7 at a rate of 1 µL/min. Immediately following CED, the mice were transferred to a 7 Tesla 122 MRI machine to visualize changes in galbumin distribution over time. Five representative slices are 123 shown for one mouse. T2-weighted images were used to identify the location of the tumors (Suppl. Following CED, the number of invading cells significantly increased to 12.2 ± 2.4/mm 2 ( Fig. 3E-F 
, K) 132
(t(12)=2.433, n=7, p<0.05). This greater than 2-fold increase to invasion in vivo was even more 133 pronounced than the in vitro results (increased approximately 1.5-fold under flow). 134
Effects of flow in vivo are mediated through CXCR4 135
Given the ability of CXCR4 antagonism to reduce flow-stimulated invasion in vitro, we also examined 136 the effects of administering the CXCR4 antagonist AMD3100 (5 mg/kg) systemically with and without 137 CED 11 . This drug has been delivered to in vivo glioma models previously and shows some clinical 138 potential as a secondary therapy 12-14 . In the absence of convective flow ( Fig. 3G-H, K) , AMD3100 did 139 not significantly alter glioma cell invasion compared to untreated controls at 5.12 ± 0.490/mm 2 140 (t(12)=0.6008, n=7, p>0.1). However, applying CED in mice treated with AMD3100 ( Fig. 3I-J, K ) 141 significantly reduced the effects of flow on invasion compared to CED alone (t(12)=3.026, n=7, p<0.05). 142
This treatment regimen effectively maintained the number of cells invading beyond the tumor border to 143 4.38 ± 0.731 cells/mm 2 , not significantly different from that of untreated, static controls. Hence, dosing 144 with AMD3100 prior to convection is able to mitigate flow-stimulated increases to glioma cell invasion. 145
This decrease in flow-stimulated invasion with AMD3100 treatment was associated with a decrease in 146 moderate immunoreactivity for phosphorylated CXCR4 (Fig. 4A) , indicating that this signaling pathway 148 is basally active within GL261 tumors in vivo. Consistent with prior in vitro results, applying flow via 149 CED markedly increased pCXCR4 immunoreactivity in vivo (Fig. 4B) . Administering AMD3100 prior to 150 CED effectively attenuated increased pCXCR4 staining, observably decreasing immunoreactivity below 151 that of untreated controls (Fig. 4C) . No qualitative differences were observed in total CXCR4 expression 152 (data not shown). Hence, interstitial flow is indeed able to stimulate invasion of glioma cells in vivo 153 mediated at least in part through CXCR4 signaling. 154 meaning it is implemented after the standard of care radiation therapy and chemotherapy. Therefore, it is 157 important to consider the implications of therapy on the predisposition to flow stimulated cancer cell 158 invasion. We qualitatively examined the expression of CXCR4 and CXCL12 in samples obtained from 159 six patients diagnosed with glioblastoma prior to their receiving therapy and six patients after standard of 160 care therapy ( Fig. 5A-H) . CXCL12 staining was generally more intense and widespread throughout the 161 positive for CXCR4 and many nuclei in the malignant regions did not appear to be associated with 163 CXCR4 reactivity ( Fig. 5A-B) . Conversely, staining intensity appeared greater in samples obtained from 164 patients who received therapy ( Fig. 5C-D) . Similar trends were also observed for CXCL12 staining, with 165 perhaps a more dramatic difference between pre-therapy samples (Fig. 5E-F) and post-therapy samples 166 ( Fig. 5G-H) . 167
Discussion 168
Interstitial fluid flow is a key component of normal physiology; however, emerging evidence 169
suggests that this biomechanical force may also contribute to cancer malignancy (Munson and Shieh, 170 2014 ). The phenomenon is studied most extensively in breast cancer, where interstitial flow influences 171 both the direction and magnitude of cancer cell migration and promotes activation of, and matrix 172 remodeling by, relevant stromal cells 5,15-18 . Regarding GBM, paths of brain tumor dissemination 173 correlate with bulk fluid pathways 19 . Only recently we showed that interstitial flow indeed increases 174 invasion of both murine and human glioma cells through the chemokine receptor-ligand pair CXCR4 and 175 CXCL12 6,7 . Nonetheless, the causal effects of flow on cancer cell invasion are currently known 176 exclusively from in vitro experiments since previous in vivo data is only correlative. The goal of the 177 current study was to elucidate the ability for interstitial fluid flow to directly stimulate glioma cell 178 invasion in the brain. 179
The therapeutic technique of convection enhanced delivery (CED) was used to induce convective 180 flow in situ within brain tumors, as evidenced by rapid contrast agent elimination. CED, a catheter-based 181 method to by-pass transport limitations between the vasculature and the high-pressure tumor bulk, has 182 been used experimentally and tested clinically for enhancing local perfusion of chemotherapeutics or 183 other drugs in the treatment of GBM 10,20,21,22 . It was found that applying CED at 1 µL/minthe lower 184 end of the clinically-relevant range of 1-5 µL/min 9significantly increased GL261 cell invasion 185 compared to untreated controls, based on analysis two days after flow application. This greater than 2-186 fold differential was more pronounced than in comparative in vitro experiments, suggesting an enhanced 187 contribution of flow-stimulated invasion in vivo. One possible explanation for this pronounced effect is 188 that CXCR4 expression was found to dramatically increase on GL261 cells upon implantation (from 8.13 189 ± 1.71% in 3D to 65.4 ± 5.19% in vivo, p<0.0001). 190
Because glioma cells can also express CXCL12, the ligand for CXCR4, it has been proposed that 191 interstitial flow stimulates migration through a mechanism termed autologous chemotaxis 1, 5 . Essentially, 192 in vitro and in silico experiments suggest that fluid flow creates an anisotropic ligand gradient around 193 individual cells in the direction of flow to stimulate directional migration. We previously showed using an 194 agent based model that only small populations of CXCR4-and CXCL12-expressing cells are required to 195 exhibit a flow response through this mechanism 7 . A drastic increase in CXCR4 expression in vivo may 196 therefore greatly increase the likelihood of flow-stimulated invasion. Furthermore, although CXCL12 197 expression did not vary significantly between 3D culture and in vivo, CXCL12 is produced by other cells 198 such as endothelial cells and astrocytes and is also present in the blood 23-25 . Therefore, ligand availability 199 likely increases upon implantation, independent of cancer cell expression. 200
In the absence of any treatment, we observed moderate reactivity for CXCR4 phosphorylation, a 201 known marker of receptor activation and signaling. Convective flow increased phospho-CXCR4 202 immunoreactivity both in the tumor and healthy brain tissue, suggesting the technique of CED may 203 increase chemokine signaling and thus tumor cell dissemination. Additionally, there may be further 204 implications of increased CXCR4 phosphorylation in the brain since activation of CXCR4 in glia can lead 205 to increased neurotoxicity and pro-tumor phenotypes 26, 27 . Additional studies are required to examine if 206 the negative implications of CED (increased invasion and CXCR4 phosphorylation) are counter-balanced 207 by the cytotoxic effects of an infused drug. 208
Other mechanisms have also been implicated in cancer cell response to flow. In particular, the 209 hyaluronan-rich glycocalyx can mediate flow-driven mechanotransduction in part through the hyaluronan 210 receptor CD44 28 . We observed here that CXCR4 signaling may be a primary mechanism by which the 211 dependence on CXCR4, CD44, or both for flow-stimulated invasion 7 . Additionally, blocking CXCR4 did 213 not eliminate invasion entirely under static or flow conditions. Cancer cell invasion is a multifaceted 214 process regulated by many mechanisms, as previously reviewed by Sayegh et al. 29 . Thus, here we 215 identified CXCR4 as a regulator of flow-mediated glioma cell invasion, but other mechanisms can 216 concurrently enhance infiltration into the brain. 217
While not examined here, it is important to consider that CED is most often used experimentally 218 after standard radiation and chemotherapy. Previous work demonstrated that radiation induces tumor 219 invasiveness by increasing tumor-derived CXCL12 at the invasive tumor border, which may enhance the 220 potential for CXCR4 signaling 30 . Furthermore, irradiation of GL261 cells increased CXCR4 expression 221 in a dose-dependent manner 31 . Using patient samples, we observed that post-therapy samples had 222 increased immunoreactivity for both CXCR4 and CXCL12 compared to samples obtained pre-therapy. 223
These observations suggest that the increased expression found in mice after therapy may hold true in 224 humans. Beyond chemokine signaling, CXCR4 is also a purported marker of glioma stem cells 32 ; 225 therefore, increases to CXCR4 expression due to radiation may not only increase the potential for flow-226 stimulated invasion but also increase malignancy via cancer stem cell expansion. Our data imply that 227 therapeutic use of CED, while advantageous for increasing drug transport and overall patient survival, 228 may benefit from supplementation with CXCR4 blockade to preserve the benefit on drug permeance 229 while preventing undesirable increases to cancer cell invasion. 230
Materials and Methods 231
In vitro invasion assays 232 GL261 invasion was assessed in vitro using 12-well (Millipore PI8P01250) or 96-well (Corning 233 3374) tissue culture inserts 1 . Cancer cells were seeded at 1 x 10 6 cells/mL in 3D hydrogels, as described 234 above. After 20 minutes of gelation, 15 μL of fresh medium was applied on top of the gels. Flow was 235 was used at 10 μM (Sigma A5602) to block the receptor CXCR4 while an excess of 100 nM CXCL12 237 (Peprotech 300-28A) was added to prevent chemokine gradient formation. The membranes were then 238 fixed in 4% paraformaldehyde and counterstained using DAPI (Thermo Fisher D1306). An EVOS FL 239 fluorescence microscope was used to acquire 20X images of the porous membrane bottom at five random 240 locations for each sample 33 . The number of invading cells was manually counted for each technical 241 replicate for n ≥ 4 biological replicates. coordinates -2, +2, -2.2 (AP, ML, DV) from bregma. 100,000 GFP + GL261 cells were inoculated in 5 μL 250 at 1 μL/min, and the bur hole was sealed with bone wax. Ketoprofen was administered at 2 mg/kg for 48 251 hours to manage pain. One week later, the inoculation site was re-exposed, and a blunt-end 26 gauge 252 needle was used to infuse 10 μL of 1 mg/mL biotinylated dextran amine at 1 μL/min. Ketoprofen was 253 again administered at 2 mg/kg for 48 hours to manage pain. 254
Flow cytometry 255
Triplicate wells of 100,000 GL261 cells were cultured in serum-containing medium overnight, 256 either on 2D tissue culture plastic or in 3D hydrogels comprising 1.5% rat tail collagen (Corning 354236), 257 0.2% thiolated hyaluronic acid (Glycosil®; ESI Bio GS220), and 0.1% PEGDA (ESI Bio GS3006). The 258 following day, cells were cultured with 10 μM Brefeldin A for 6 hours, harvested, pooled, and subjected 259 above, and 14 days post-implantation mice were treated with 0.25 mg Brefeldin A for 6 hours via 261 intraperitoneal injection 34 . The brains were then dissociated for analysis. Briefly, the ipsilateral cortical 262 hemisphere was isolated into HBSS and slightly trimmed to reduce the number of non-cancerous cells. 263
The tissue was minced using a scalpel blade, incubated in 5 mL of ACK RBC lysis buffer for 3-5 minutes 264 at room temperature, and centrifuged at 1100 rpm for 5 minutes. An approximately equal volume of 1.5 265 mg/mL Liberase DL (Sigma 5466202001) was then added to digest the tissue for 30 minutes on a rocker 266 at 37°C, pipetting up and down to ensure complete digestion. 267
The tissue slurry was then strained through a 40 micron cell strainer followed by 35 mL of HBSS. 268
This solution was centrifuged at 1100 rpm for 5 minutes, and the isolated cells were resuspended and 269 counted for flow cytometry. Primary-conjugated antibodies were used to stain for CXCR4 (eBiosciences 
Tissue harvest and immunohistochemistry 291
Two days after convection enhanced delivery, tumor-bearing mice were overdosed on Euthasol 292 solution and intracardially perfused with phosphate buffered saline (PBS). Brain tissue was quickly 293 harvested and bisected at the center of the injection site. The brains were fixed overnight in 4% 294 paraformaldehyde, cryopreserved in 30% sucrose, and sectioned at 12 µm using a Leica 1950 cryostat. 295
Tissue sections were blocked in 3% serum and 0.03% Triton X-100 in PBS for 1 hour, then were 296 incubated overnight at 4 °C with rabbit anti-pCXCR4 (Abcam ab74012) diluted in blocker buffer. The 297 samples were washed three times with PBS and incubated for 1 hour at room temperature with goat anti-298 rabbit 660 diluted in blocking buffer. After washing again, the nuclei were counterstained using DAPI 299 (Thermo Fisher). 300
In vivo invasion quantification 301
Fluorescently labeled sections were imaged using an EVOS FL microscope. Five images were 302 randomly taken around the tumor periphery for each of three sections 120 μm apart for each animal. The 303 tumor border was identified based on GFP + GL261 and nuclear staining, and a blinded investigator 304 counted the number of GFP + tumor cells beyond the border for each image. Data is presented as the 305 number of invading cells per mm 2 of tissue. with ethanol:water to achieve rehydration. The samples were then subjected to boiling in citrate buffer for 313 30 minutes for antigen retrieval. The same primary antibodies were used as above: CXCR4 (Sigma 314 GW21075) and CXCL12 (Abcam ab18919). Samples for CXCR4 were treated with goat anti-chicken IgY 315 HRP secondary (Abcam ab97135) and those for CXCL12 with ImmPRESS™ horse anti-rabbit IgG HRP 316 (Vector Labs MP-7401) prior to development with DAB. Images were acquired using an Aperio Slide 317
Scanner and processed using ImageScope. Qualitative assessment was conducted on samples from a six 318 patients per stain for each therapy status. 319
Statistics 320
Analysis of Variance (ANOVA) was performed for comparisons of more than two groups, using 321 a significance level of 0.05. If significance was identified within the dataset, t-tests were performed to 322 determine significance between individual groups. Ratio paired t-tests were used to analyze all in vitro 323 data; unpaired t-tests were used to compare in vitro data to in vivo flow cytometry data; and unpaired 324 student's t-tests were used to compare experimental groups for in vivo invasion. All graphed and reported 325 descriptive statistics in the text are presented as mean ± standard error of the mean, unless otherwise 326 stated. Inferential statistics are reported as statistics (degrees of freedom)=value, n per group, p value so 327 that effect size can be determined from our reported data. 328
